FacebookTwitterGoogle+RedditEmail

A Small Item on the Business Page

by FRED GARDNER

A small item on the business page, forwarded by Sunil Aggarwal, MD: Sanofi, the French manufacturer of Rimonabant —a drug that reduces appetite by blocking an endocannabinoid receptor— has agreed to pay $40 million to U.S. investors who had been misled by claims that the compound’s safety had been proven in clinical trials.

Sanofi won approval to market Rimonabant from the European Medicines Agency (EMEA) in June 2006. Tor Gronbaum, the attorney representing U.S investors who bought Sanofi stock following the EMEA approval, told your correspondent that “suicidality” was the main adverse effect concealed by Sanofi. The terms of the settlement kept him from discussing its details, but Gronbaum said that he, personally, was unaware that other harmful effects had been credibly attributed to Rimonabant.

This is significant because corporate pharmacologists are still working on “cannabinoid antagonist” drugs that don’t cross the blood-brain barrier (and supposedly don’t affect mood). They have successfully convinced people that Rimonabant’s sole tragic flaw was its impact on mood.

Sanofi would have saved the $40 million pay-out, plus the approximately 750 million euros  spent bringing Rimonabant to market, had their top scientists heeded a warning from Jeffrey Hergenrather, MD, a country doctor from Sebastopol, California, at the 2004 meeting of the International Cannabinoid Research Society.

CounterPunch broke this story in a July 2004 piece called “The Year of the Antagonist.” O’Shaughnessy’s ran it in the Autumn 2004 issue:

“Scientists employed by Sanofi reported at the 2004 meeting of the International Cannabinoid Research Society that Rimonabant has proven safe and effective in clinical trials involving 13,000 patients…

But the advent of Rimonabant troubles California doctors who have made a specialty of monitoring their patients’ cannabis use, as well as some scientists who are studying the basic nature of the cannabinoid system.

Jeffrey Hergenrather, MD, of Sebastopol  —one of the few clinicians to attend this year’s ICRS meeting—  warned, “We are only now becoming aware of the modulating effects the cannabinoids have on the body and mind. The consequences of interfering with the cannabinoid receptor system have not been evaluated in normal human physiology.”

Before marketing commenced, Hergenrather adivsed, “It would be ethical to design longitudinal studies to assess the consequences of interfering with the cannabinoid system.”

Our story was slugged “Danger Danger Danger!”   It explained that Rimonabant is an “antagonist” drug that engages the CB1  receptors so they can’t be activated. Originally called SR-141716, it was developed by Sanofi in the early ’90s as a tool for researchers investigating the endocannabinoid system. If a given effect is blocked by SR-141716, that effect is said to be “mediated” by CB1  receptors.

Being able to determine which metabolic effects involve CB1 receptors  was a huge step forward for ICRS scientists. In recent years, numerous talks and posters have described what happens when SR-141716 is administered to rodents. Sure enough, appetite suppression was observed consistently.

Rimonabant is SR-141716 redefined as a “therapeutic drug” that counteracts unwanted effects mediated by the cannabinoid receptor system —like overeating.

Asked at the 2004 ICRS meeting how a drug could block the CB1 receptor system without adversely affecting mood, sleep, pain relief, and other CB1-mediated aspects of well-being, the Sanofi researchers answered vaguely that other neurotransmitters were likely to play compensatory roles. No pattern of adverse effects had been observed during the clinical trials, they claimed. Such effects were assumed to be so rare that they would not be detectable until Rimonabant had been used by millions of people over a period of years.

There were a few whispered criticisms and misgivings. A multiple sclerosis specialist told of a case in which Rimonabant apparently caused an immediate, extreme exacerbation.  A physician wondered —since the body’s own  cannabinoids have neuroprotectant and anti-oxidant functions—if Rimonabant users would be at increased risk for stroke and cancer.  But the negative remarks were anecdotal or speculative; the positive data belonged to Sanofi.

Three Sanofi Rechercheurs accepted the ICRS’s 2004 achievement award on behalf of their company. It was presented by Raphael Mechoulam, the grand old man of the field, who wryly observed that Sanofi had shown great foresight in developing a weight-loss drug in the 1990s, because it had since swallowed up two much larger drug companies, Synthelabo and Aventis. (Today Sanofi is the world’s fourth largest pharmaceutical company in terms of sales).

Sanofi won approval from the EMEA to sell Rimonabant in 25 countries under various names devised by their marketing wizards. In England it was called “Acomplia.”  The name in the U.S. was going to be “Zimulti.” But a funny thing happened on the way to Zimulti in the spring of 2007. The death toll from Vioxx had reached 50,000 —probably the most suppressed fact of the past decade— and the physicians on the U.S. Food and Drug Administration committee were, to use Gronbaum’s term, “spooked.” Hergenrather’s colleague Tod Mikuriya, MD, had written a letter to the FDA advising against approval, and he felt a small sense of achievement when the advisory committee announced its unanimous “Nix!”

In June 2008 the European Medicines Agency reviewed data from Sanofi’s clinical trials and withdrew its approval. Rimonabant users were found to suffer depression, anxiety, insomnia and aggressive impulses at twice the rate of subjects given placebo. In one study there were five suicides among Rimonabant users compared to only one among subjects on placebo. By not presenting the results of this study, Sanofi misled investors in the period between European approval and FDA rejection.

Unpublicized to date are adverse effects involving cancer, seizures, and other illnesses that the endocannabinoid system plays a role in suppressing.

 Fred Gardner is the managing editor of O’Shaughnessy’s, the journal of cannabis in clinical practice, now online at beyondthc.com

 

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

January 16, 2017
Paul Street
How Pure is Your Hate?
Jeffrey St. Clair - Alexander Cockburn
Did the Elites Have Martin Luther King Jr. Killed?
Robert Hunziker
Global Warming Clobbers Ocean Life
Patrick Cockburn
The Terrifying Parallels Between Trump and Erdogan
Kenneth Surin
The Neoliberal Stranglehold on the American Public University
Lawrence Davidson
Is There a Future for the Democratic Party?
Douglas Valentine
Who Killed MLK Jr?
Robert Fisk
The Foreign Correspondent in the Age of Twitter and Trump
Dale Bryan
“Where Do We Go from Here?”
David Swanson
The Deep State Wants to Deep Six Us
Dan Bacher
Obama Administration Orders Speedy Completion of Delta Tunnels Plan
Mark Weisbrot
Obama Should Make Sure that Haitian Victims of UN-Caused Cholera are Compensated
Winslow Myers
The Light of the World
Bruce Mastron
My Latest Reason to Boycott the NFL: Guns
Weekend Edition
January 13, 2017
Friday - Sunday
Gregory Elich
Did the Russians Really Hack the DNC?
Jeffrey St. Clair
The President Who Wasn’t There: Barack Obama’s Legacy of Impotence
Anthony DiMaggio
Ethics Fiasco: Trump, Divestment and the Perversion of Executive Politics
Joshua Frank
Farewell Obummer, Hello Golden Showers
Paul Street
Hit the Road, Barack: Some Farewell Reflections
Vijay Prashad
After Aleppo: the State of Syria
John Wight
Russia Must be Destroyed: John McCain and the Case of the Dodgy Dossier
Rob Urie
Meet the Deplorables
Patrick Cockburn
The Russian Dossier Reminds Me of the Row Over Saddam’s WMDs
Eric Sommer
U.S.-China War: a Danger Hidden from the American People
Andrew Levine
Are Democrats Still the Lesser Evil?
Linda Pentz Gunter
What’s Really Behind the Indian Point Nuclear Deal?
Robert Fantina
Trucks, ‘Terror’ and Israel
Richard Moser
Universal Values are Revolutionary Values
Russell Mokhiber
Build the Bagdikian Wall: “Sponsored News” at the Washington Post
Yoav Litvin
Establishment Narcissism – The Democrats’ Game of Thrones
David Rosen
Return of the Repressed: Trump & the Revival of the Culture Wars
Robert Koehler
War Consciousness and the F-35
Rev. William Alberts
The New Smell of McCarthyism Demands Faith Leaders Speak Truth to Power
John Laforge
Federal Regulator Halts Move to Toughen Radiation Exposure Limits
Norman Pollack
Farewell Address: Nazification of Hope
David Swanson
Imagine the Confirmation Hearing for Secretary of Peace
CJ Hopkins
Why Ridiculous Official Propaganda Still Works
Ron Jacobs
Striking in Reagan Time
Missy Comley Beattie
The Streep
Graham Peebles
Climate Change: The Potential Impacts of Collective Inaction
Uri Avnery
Confessions of a Megalomaniac
Kenneth Worles
Black Without a Home: King’s Dream Still Deferred
Geoff Dutton
The Russian Patsy
Jill Richardson
The Coming War on Regulations
Jeremy Brecher
Resisting the Trump Agenda is Social Self-Defense
FacebookTwitterGoogle+RedditEmail